Effect of abatacept versus conventional synthetic disease modifying anti-rheumatic drugs on rheumatoid arthritis-associated interstitial lung disease
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: To compare the effects of abatacept and conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) on the progression and development of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Methods: This multi-center retrospective study included RA patients receiving abatacept or csDMARDs who underwent at least two pulmonary function tests and/or chest high-resolution computed tomography (HRCT). We compared the following outcomes between the groups: progression of RA-ILD, development of new ILD in RA patients without ILD at baseline, 28-joint Disease Activity Score with the erythrocyte sedimentation rate (DAS28-ESR), and safety. Longitudinal changes were compared between the groups by using a generalized estimating equation. Results: The study included 123 patients who were treated with abatacept (n = 59) or csDMARDs (n = 64). Nineteen (32.2%) and 38 (59.4%) patients treated with abatacept and csDMARDs, respectively, presented with RA-ILD at baseline. Newly developed ILD occurred in one patient receiving triple csDMARDs for 32 months. Among patients with RA-ILD at baseline, ILD progressed in 21.1% of cases treated with abatacept and 34.2% of cases treated with csDMARDs during a median 21-month follow-up. Longitudinal changes in forced vital capacity and diffusing capacity for carbon monoxide were comparable between the two groups. However, the abatacept group showed a more significant decrease in DAS28-ESR and glucocorticoid doses than csDMARDs group during the follow-up. The safety of both regimens was comparable. Conclusions: Abatacept and csDMARDs showed comparable effects on the development and stabilization of RA-ILD. Nevertheless, compared to csDMARDs, abatacept demonstrated a significant improvement in disease activity and led to reduced glucocorticoid use.
Abstract
Background/Aims: To compare the effects of abatacept and conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) on the progression and development of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Methods: This multi-center retrospective study included RA patients receiving abatacept or csDMARDs who underwent at least two pulmonary function tests and/or chest high-resolution computed tomography (HRCT). We compared the following outcomes between the groups: progression of RA-ILD, development of new ILD in RA patients without ILD at baseline, 28-joint Disease Activity Score with the erythrocyte sedimentation rate (DAS28-ESR), and safety. Longitudinal changes were compared between the groups by using a generalized estimating equation. Results: The study included 123 patients who were treated with abatacept (n = 59) or csDMARDs (n = 64). Nineteen (32.2%) and 38 (59.4%) patients treated with abatacept and csDMARDs, respectively, presented with RA-ILD at baseline. Newly developed ILD occurred in one patient receiving triple csDMARDs for 32 months. Among patients with RA-ILD at baseline, ILD progressed in 21.1% of cases treated with abatacept and 34.2% of cases treated with csDMARDs during a median 21-month follow-up. Longitudinal changes in forced vital capacity and diffusing capacity for carbon monoxide were comparable between the two groups. However, the abatacept group showed a more significant decrease in DAS28-ESR and glucocorticoid doses than csDMARDs group during the follow-up. The safety of both regimens was comparable. Conclusions: Abatacept and csDMARDs showed comparable effects on the development and stabilization of RA-ILD. Nevertheless, compared to csDMARDs, abatacept demonstrated a significant improvement in disease activity and led to reduced glucocorticoid use.
참고문헌 (30)
- Laria A, "Interstitial lung disease in rheumatoid arthritis : a practical review", Front Med(Lausanne), 9, pp.837133~ (2022)
- Brito Y, "Rheumatoid arthritis-associated interstitial lung disease : current concepts", Curr Rheumatol Rep, 19, pp.79~ (2017)
- Huang S, "Rheumatoid arthritis-associated interstitial lung disease : current update on prevalence, risk factors, and pharmacologic treatment", Curr Treatm Opt Rheumatol, 6, pp.337~353 (2020)
- Kiely P, "Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts", BMJ Open, 9, pp.e028466~ (2019)
- Juge PA, "Methotrexate and rheumatoid arthritis associated interstitial lung disease", Eur Respir J, 57, pp.2000337~ (2021)
- Akiyama M, "Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease", Autoimmun Rev, 21, pp.103056~ (2022)
- Fernández-Díaz C, "Abatacept in patients with rheumatoid arthritis and interstitial lung disease : a national multicenter study of 63 patients", Semin Arthritis Rheum, 48, pp.22~27 (2018)
- Fernández-Díaz C, "Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients", Rheumatology(Oxford), 61, pp.299~308 (2021)
- Holroyd CR, "The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis-Executive summary", Rheumatology(Oxford), 58, pp.220~226 (2019)
- Aletaha D, "2010 Rheumatoid arthritis classification criteria : an American College of Rheumatology", European League Against Rheumatism collaborative initiative, 2010, pp.62, 2569~2581
- Arnett FC, "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis", Arthritis Rheum, 31, pp.315~324 (1988)
- Lee KA, "Clinical course and risk factors for development and progression of interstitial lung disease in primary Sjögren’s syndrome", Sci Rep, 13, pp.9189~ (2023)
- Kim JW, "Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease", Rheumatology(Oxford), 62, pp.2377~2385 (2023)
- American Thoracic Society, "American Thoracic Society", European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society(ATS), and the European Respiratory Society(ERS)was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001, 2002, pp.165, 277~304
- Vicente-Rabaneda EF, "Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis : a systematic literature review", Autoimmun Rev, 20, pp.102830~ (2021)
- Cassone G, "Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease : a multicenter retrospective study", J Clin Med, 9, pp.277~ (2020)
- Pombo-Suarez M, "Abatacept for the treatment of rheumatoid arthritis", Expert Rev Clin Immunol, 15, pp.319~326 (2019)
- Courvoisier DS, "The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents : results from a collaboration of 16 registries", Rheumatology(Oxford), 60, pp.820~828 (2021)
- Mena-Vázquez N, "Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis", Clin Rheumatol, 40, pp.133~142 (2021)
- Nakashita T, "Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients", Respir Investig, 54, pp.376~379 (2016)
- Mochizuki T, "Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept", Mod Rheumatol, 29, pp.413~417 (2019)
- Kim K, "Protective effect of methotrexate on lung function and mortality in rheumatoid arthritis-related interstitial lung disease : a retrospective cohort study", Ther Adv Respir Dis, 16, pp.17534666221135314~ (2022)
- Xu J, "Methotrexate use reduces mortality risk in rheumatoid arthritis : a systematic review and meta-analysis of cohort studies", Semin Arthritis Rheum, 55, pp.152031~ (2022)
- Harigai M, "Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis", Mod Rheumatol, 26, pp.491~498 (2016)
- Weinblatt ME, "Safety of abatacept administered intravenously in treatment of rheumatoid arthritis : integrated analyses of up to 8 years of treatment from the abatacept clinical trial program", J Rheumatol, 40, pp.787~797 (2013)
- Raghu G, "Idiopathic pulmonary fibrosis(an update)and progressive pulmonary fibrosis in adults : an official ATS", ERS, ALAT clinical practice guideline, pp.Am J Respir Crit Care Med, 2022[DOI]
- Nathan SD, "Using forced vital capacity(FVC)in the clinic to monitor patients with idiopathic pulmonary fibrosis(IPF) : pros and cons", Expert Rev Respir Med, 15, pp.175~181 (2021)
- Flaherty KR, "Nintedanib in progressive fibrosing interstitial lung diseases", N Engl J Med, 381, pp.1718~1727 (2019)
- George PM, "Progressive fibrosing interstitial lung disease : clinical uncertainties, consensus recommendations, and research priorities", Lancet Respir Med, 8, pp.925~934 (2020)
- Hilberg O, "Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries", ERJ Open Res, 8, pp.00597-2021~ (2022)